◀ Back to MTOR

IL2 — MTOR

Pathways - manually collected, often from reviews:

• NCI Pathway Database Regulation of Telomerase: IL2 (IL2) → mTOR (MTOR) (modification, activates) Haendeler et al., FEBS Lett 2003
  Evidence: assay

Text-mined interactions from Literome

Kawauchi et al., J Immunol 2005 (Leukemia, Lymphocytic, Chronic, B-Cell...) : IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells
Marzec et al., Blood 2008 (Lymphoma, T-Cell, Cutaneous) : The mTORC1 , PI3K/Akt, and MEK/ERK pathways could also be activated by IL-2 in the primary leukemic, mitogen preactivated CTCL cells
Ohtani et al., Blood 2008 (Leishmaniasis, Cutaneous) : Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide induced interleukin-12 production in dendritic cells